| Name | Title | Contact Details |
|---|
DataCoining Exists To Empower Your Ability To Craft, Protect And Monetize – The Data Of You™.
MotoRad Ltd. is a global manufacturer of automotive components, specializing in thermal management systems. Established in 1958 and originally known as Fishman Engineering Ltd., the company is now owned by Fortissimo Investment Funds and employs 156 people. In 2025, MotoRad reported an annual revenue of $28.7 million, with Matt Buchholz serving as CEO. The company develops and manufactures a range of thermal management solutions, including thermostats, caps, and sensors. These products are designed for internal combustion engines, hybrid vehicles, plug-in hybrids, and battery electric vehicles. MotoRad serves automotive OEMs, aftermarket distributors, and industrial applications, ensuring a high level of product availability and a 97.81% global fill rate to meet customer needs. The company emphasizes innovation and collaborative work environments, focusing on employee development and technological advancement.
Protime Sports was founded in 2007 as a factory direct supplier located in Seattle Washington. With the exception of licensed product, all uniform items sold are Protime Sports apparel which provides the purchaser with the best possible pricing. Our own manufacturing facility allows us complete product quality and control. Printing, decoration, sublimation and embroidery are done in house to assure absolute order accuracy and quick turn times. Large levels of inventory are maintained in our 55,000 square foot facility to accommodate "at once" orders during the peak of the season. Our on-site cutting and sewing operation allow for quick fill-ins when product is running low on popular styles. We ship nationwide to baseball, soccer, basketball and volleyball clubs and organizations. We offer customers a wide range of tools to help make the ordering process as simple and clear as possible. Protime Sports will supply clubs with size samples, pre-order checklists, product samples and mock-up as well as an impressive spirit wear program. We strive to offer flexibility and diversity to meet your needs and expectations. Through honesty and integrity, our goal remains to deliver premier quality uniforms on time, with the best customer service in the industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.